Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023, compared with $666.8 million for the year ended December 31, 2022.

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM EST) on Wednesday, January 10, 2024. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Arlo Technologies Inc

Catalyst Pharmaceuticals

Digi

Dynavax Technologies

Green Plains

Helix Energy Solutions Group

Ironwood Pharma

Ligand Pharmaceuticals

Livent Corp

ModivCare

Payoneer Global

Patterson-UTI Energy

Arcus Biosciences

SMART Global Hlds

Talos Energy Inc

Vir Biotechnology

Xencor

Xperi

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:

20 favorite small-cap stocks for 2024 among Wall Street analysts

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board --

Pacira Appoints Frank D. Lee as Chief Executive Officer

The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by.

Pacira BioSciences, Inc. (PCRX) Q3 2023 Earnings Call Transcript

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Pacira (PCRX) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.64 per share a year ago.

Pacira (PCRX) Misses Q3 Earnings and Revenue Estimates

-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 --

Pacira BioSciences Reports Third Quarter 2023 Financial Results

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) to Report Q3 Results: Wall Street Expects Earnings Growth

TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023

SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA's Industry Supporter Program to support the Society's more than 56,000 physician anesthesiologist members to improve patient care and reduce reliance on opioids for the treatment of postsurgical or chronic pain.

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

SCHAUMBURG, Ill. and TAMPA, Fla., Oct. 02, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 million, by Pacira to the ASA Charitable Foundation, to advance the medical specialty of anesthesiology and pain medicine; facilitate best-in-class clinician education; and improve patient care.

American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care

David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that David (“Dave”) Stack will retire from his role as Chairman and Chief Executive Officer.

Pacira BioSciences Announces Leadership Succession Plan

TAMPA, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced its participation in an analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference.  The pre-recorded audio of the virtual event can be accessed beginning Monday, September 11th at 7:00AM ET by visiting the “Events” page of the company's website at investor.pacira.com . A replay of the webcast will also be available for two weeks.

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Rohit Bhasin - Needham & Company Boris Peaker - TD Cowen Operator Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call.

Pacira BioSciences, Inc. (PCRX) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Pacira (PCRX) Q2 Earnings: A Look at Key Metrics

Pacira (PCRX) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.51 per share a year ago.

Pacira (PCRX) Lags Q2 Earnings and Revenue Estimates

-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.

News for Pacira Pharmaceuticals Stock (PCRX)